Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Cigna subsidiary Evernorth Health Services will authorize prior authorizations for GLP-1 weight-loss drugs under a new ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

The FDA has approved medications like Zepbound and Wegovy for weight loss, which use the same active ingredient as the ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

With Zepbound at Its Core, The Naderi Center's New Initiative Addresses Male Weight Loss and Facial Rejuvenation Through ...